WFRF:(Pollack Charles V.)
Sökning: WFRF:(Pollack Charles V.) > (2016) > Apixaban compared w...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04283naa a2200421 4500 | |
| 001 | oai:DiVA.org:uu-305538 | |
| 003 | SwePub | |
| 008 | 161019s2016 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3055382 URI |
| 024 | 7 | a https://doi.org/10.1016/j.ahj.2016.06.0082 DOI |
| 040 | a (SwePub)uu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Ezekowitz, Michael D.u Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.;Lankenau Med Ctr, Wynnewood, PA USA.4 aut |
| 245 | 1 0 | a Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion :b Rationale and design of the EMANATE trial |
| 264 | 1 | b Elsevier BV,c 2016 |
| 338 | a electronic2 rdacarrier | |
| 520 | a Background: Stroke prevention in anticoagulation-nafve patients with atrial fibrillation undergoing cardioversion has not been systematically studied.Objective: To determine outcomes in anticoagulation-naive patients (defined as those receiving an anticoagulant for <48 hours during the index episode of atrial fibrillation) scheduled for cardioversion.Methods: This is a randomized, prospective, open-label, real-world study comparing apixaban to heparin plus warfarin. Early image-guided cardioversion is encouraged. For apixaban, the usual dose is 5 mg BID with a dose reduction to 2.5 mg BID if 2 of the following are present: age >80 years, weight <60 kg, or serum creatinine >1.5 mg/dL. If cardioversion is immediate, a single starting dose of 10 mg (or 5 mg if the dose is down-titrated) of apixaban is administered. Cardioversion may be attempted up to 90 days after randomization. Patients are followed up for 30 days after cardioversion or 90 days postrandomization if cardioversion is not performed within that timeframe. Outcomes are stroke, systemic embolization, major bleeds, clinically relevant nonmajor bleeding, and death, all adjudication-blinded.Statistics: The warfarin-naive cohort from the ARISTOTLE study was considered the closest data set to the patients being recruited into this study. The predicted incidence of stroke, systemic embolism, and major bleeding within 30 days after randomization was approximately 0.75%. To adequately power for a noninferiority trial, approximately 48,000 participants would be needed, a number in excess of feasibility. The figure of 1,500 patients was considered clinically meaningful and achievable. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
| 700 | 1 | a Pollack, Charles V.u Thomas Jefferson Univ, Philadelphia, PA 19107 USA.4 aut |
| 700 | 1 | a Sanders, Paulu Pfizer, London, England.4 aut |
| 700 | 1 | a Halperin, Jonathan L.u Icahn Sch Med Mt Sinai, New York, NY 10029 USA.4 aut |
| 700 | 1 | a Spahr, Judithu Lankenau Inst Med Res, Wynnewood, PA USA.4 aut |
| 700 | 1 | a Cater, Nilou Pfizer, New York, NY USA.4 aut |
| 700 | 1 | a Petkun, Williamu Bristol Myers Squibb Inc, Princeton, NJ USA.4 aut |
| 700 | 1 | a Breazna, Andreiu Pfizer, New York, NY USA.4 aut |
| 700 | 1 | a Kirchhof, Paulusu Univ Birmingham, SWBH UHB NHS Trusts, Inst Cardiovasc Sci, Birmingham, W Midlands, England.;Univ Hosp Munster, Dept Cardiol & Angiol, Munster, Germany.4 aut |
| 700 | 1 | a Oldgren, Jonasu Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)jonaoldg |
| 710 | 2 | a Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.;Lankenau Med Ctr, Wynnewood, PA USA.b Thomas Jefferson Univ, Philadelphia, PA 19107 USA.4 org |
| 773 | 0 | t American Heart Journald : Elsevier BVg 179, s. 59-68q 179<59-68x 0002-8703x 1097-6744 |
| 856 | 4 | u https://doi.org/10.1016/j.ahj.2016.06.008y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1040296/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 | u https://doi.org/10.1016/j.ahj.2016.06.008 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-305538 |
| 856 | 4 8 | u https://doi.org/10.1016/j.ahj.2016.06.008 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Ezekowitz, Micha ...
- Pollack, Charles ...
- Sanders, Paul
- Halperin, Jonath ...
- Spahr, Judith
- Cater, Nilo
- visa fler...
- Petkun, William
- Breazna, Andrei
- Kirchhof, Paulus
- Oldgren, Jonas
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- American Heart J ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
